Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial.

Y, Huo; B, Chen; Q, Lian; S, Wang; L, Liu; D, Lu; Y, Qu; G, Zheng; L, Li; Y, Ji; G, Yin; W, Huang; Y, Xie; X, Yang; X, Gao; P, An; F, Xue; H, Li; H, Deng; L, Li; L, Pei; L, Qian

doi:10.1016/j.lanwpc.2023.100907

Public

Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial.

Shared by NobleBlocks on Sep 28, 2023 • 12:00 AM UTC

Authors:

Huo Y

Chen B

Lian Q

Abstract

<h4>Background</h4>Tafolecimab, a fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody developed for the treatment of hypercholesterolemia, demonstrated robust lipid-lowering efficacy and favorable safety in previous short-term studies. We aimed to assess the long-te...

Subject

Cardiovascular disease

Hypercholesterolemia

Low-density Lipoprotein Cholesterol

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!